Ir-192 Source 370 GBq +30% -10%, Type: Ir2.A85-2

HDR Brachytherapy with Iridium-192
For a long time the production of miniaturized sources for HDR afterloading was limited to Ir-192. For that reason, Ir-192 became the most used isotope for HDR afterloading brachytherapy worldwide and allowed to develop intracavitary, intraluminal and interstitial treatments and dose optimization as it is applied today.

Clinical Role of Ir-192
The Ir-192 source is clinically and physically well proven and understood and the most established source type in HDR brachytherapy. TG-43 data, dosimetric measurements, and Monte Carlo calculations are available and have been implemented in HDRplus and SagiPlan®. Ir-192 has been shown to be a good choice for treating gynecological, rectal, prostate, breast, esophagus, skin, and other body sites. Eckert & Ziegler BEBIG provides customers with an expansive portfolio of applicators suitable for the use with Co-60 and Ir-192.
Particularly for skin cancer treatments the Ir-192 source allows to perform streamlined and easy treatment workflows using SagiPlan® 2.2 and the Valencia skin applicator. Thanks to a special skin dose prescription feature in the treatment planning system SagiPlan®, dwell times are automatically determined based on the prescribed dose and depth. The integrated support of the Valencia Applicator enables to plan, treat and report in one system without the need for extra calculations in proprietary calculation tools.

Source Exchange Period between 3-4 months
With the initial activity of the Ir-192 of typically 481 GBq it is recommended to exchange the source every 3-4 months in order to provide appropriate dose rate and irradiation time. In order to give our customers a high degree of flexibility when changing the Ir-192 source, SagiNova® allows the user to perform the exchange without a service technician.